Compounds > 2-2-bis(hydroxymethyl)-1-azabicyclo(2-2-2-)octan-3-one

2-2-bis(hydroxymethyl)-1-azabicyclo(2-2-2-)octan-3-one and Prostatic-Neoplasms

2-2-bis(hydroxymethyl)-1-azabicyclo(2-2-2-)octan-3-one has been researched along with Prostatic-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for 2-2-bis(hydroxymethyl)-1-azabicyclo(2-2-2-)octan-3-one and Prostatic-Neoplasms

Article	Year
PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2008, Volume: 86, Issue:3 The novel agent PRIMA-1(met) can reactivate WTp53 function in MTp53-expressing cells. We investigated PRIMA-1(met) as a radiosensitizer of WTp53, p53Null or MTp53 prostate cancer cells. Radiosensitization was observed in PC3 (p53Null) cells, even under hypoxia. In certain circumstances, PRIMA-1(met) may therefore act independently of MTp53 status and WTp53 transactivation. Topics: Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Humans; Hypoxia; Male; Prostatic Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Suppressor Protein p53	2008

Article

Year

PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2008, Volume: 86, Issue:3

The novel agent PRIMA-1(met) can reactivate WTp53 function in MTp53-expressing cells. We investigated PRIMA-1(met) as a radiosensitizer of WTp53, p53Null or MTp53 prostate cancer cells. Radiosensitization was observed in PC3 (p53Null) cells, even under hypoxia. In certain circumstances, PRIMA-1(met) may therefore act independently of MTp53 status and WTp53 transactivation.

Topics: Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Humans; Hypoxia; Male; Prostatic Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Suppressor Protein p53

2008